Log In
BCIQ
Print this Print this
 

SequestOx, oxycodone/naltrexone (ELI-200)

  Manage Alerts
Collapse Summary General Information
Company Elite Pharmaceuticals Inc.
DescriptionAbuse deterrent-formulation of oxycodone and naltrexone
Molecular Target Opioid receptor (OPR)
Mechanism of ActionOpioid receptor agonist
Therapeutic ModalitySmall molecule
Latest Stage of DevelopmentRegistration
Standard IndicationPain
Indication DetailsTreat moderate to severe pain; Treat moderate to severe pain following surgery; Treat pain
Regulatory Designation U.S. - Priority Review (Treat moderate to severe pain)
PartnerEpic Pharma LLC

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments

1

0

0

$15.0M


 Deals Details
DateCompanies InvolvedDeal HeadlineTotal Deal ValueTotal Upfront CashTotal Milestone

06/09/2015

Undisclosed

Undisclosed

$15.0M

Get a free BioCentury trial today